Dx & Vx Co., Ltd. (KOSDAQ:180400)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,725.00
+120.00 (2.61%)
At close: Apr 28, 2026
135.66%
Market Cap 465.08B
Revenue (ttm) 29.36B
Net Income (ttm) -29.04B
Shares Out 98.43M
EPS (ttm) -587.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 124,044
Average Volume 274,186
Open 4,650.00
Previous Close 4,605.00
Day's Range 4,560.00 - 4,755.00
52-Week Range 1,319.00 - 5,360.00
Beta 0.23
RSI 49.43
Earnings Date May 14, 2026

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2001
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 180400
Full Company Profile

Financial Performance

In 2025, Dx & Vx's revenue was 29.36 billion, a decrease of -13.52% compared to the previous year's 33.95 billion. Losses were -29.04 billion, -38.26% less than in 2024.

Financial Statements

News

There is no news available yet.